Olatec Therapeutics

About:

Olatec is a biopharmaceutical company developing a platform to treat and prevent acute and chronic inflammatory diseases.

Website: http://www.olatec.com

Twitter/X: OlatecThera

Top Investors: Michael J. Fox Foundation, Milano Investment Partners SGR, Sanders Morris Harris, Advection Growth Capital

Description:

Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Parkinson's and Alzheimer’s disease, spinal cord injury, multiple sclerosis, type-2 diabetes, melanoma, pancreatic and breast cancers, among others. Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. Olatec was established in 2003 in New York, United States by Damaris Skouras.